Literature DB >> 17712752

Spread and epidemiology of Clostridium difficile polymerase chain reaction ribotype 027/toxinotype III in The Netherlands.

A Goorhuis1, T Van der Kooi, N Vaessen, F W Dekker, R Van den Berg, C Harmanus, S van den Hof, D W Notermans, E J Kuijper.   

Abstract

BACKGROUND: After reports of emerging outbreaks in Canada and the United States, Clostridium difficile-associated disease (CDAD) due to polymerase chain reaction ribotype 027 was detected in 2 medium-to-large hospitals in The Netherlands in 2005.
METHODS: National surveillance was initiated to investigate the spread and the epidemiology of CDAD. Microbiologists were asked to send strains recovered from patients with a severe course of CDAD or recovered when an increased incidence of CDAD was noted. A standardized questionnaire was used to collect demographic, clinical, and epidemiological patient data. Strains were characterized by polymerase chain reaction ribotyping, toxinotyping, the presence of toxin genes, and antimicrobial susceptibility.
RESULTS: During the period from February 2005 through November 2006, 1175 stool samples from 863 patients were sent from 50 health care facilities. Of these patients, 218 (25.3%) had CDAD due to ribotype 027, and 645 patients (74.7%) had CDAD due to other ribotypes, mainly 001 (17.8%) and 014 (7.2%). Polymerase chain reaction ribotype 027 was more frequently present in general hospitals than in academic hospitals (odds ratio [OR], 4.38; 95% confidence interval [CI], 1.60-12.0). Outbreaks of CDAD were observed in 10 hospitals and in 1 nursing home. Patients infected with ribotype 027 were significantly older (OR, 2.18; 95% CI, 1.43-3.33), and significantly more patients used fluoroquinolones (OR, 2.88; 95% CI, 1.01-8.20), compared with those who were infected with other ribotypes. Clear trends were observed for more severe diarrhea (OR, 1.99; 95% CI, 0.83-4.73), higher attributable mortality (6.3% vs. 1.2%; OR, 3.30; 95% CI, 0.41-26.4), and more recurrences (OR, 1.44; 95% CI, 0.94-2.20).
CONCLUSIONS: Ribotype 027 was found in 20 (18.3%) of 109 hospitals in The Netherlands, with a geographic concentration in the western and central parts of the country. The clinical syndrome in patients with CDAD differed on the basis of ribotype. Thus, early recognition of the ribotype has benefits.

Entities:  

Mesh:

Year:  2007        PMID: 17712752     DOI: 10.1086/520984

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  52 in total

1.  Clostridium difficile O27 colitis: hospital-onset but community-acquired.

Authors:  S Buffet-Bataillon; P Tattevin; H Sénéchal; M Cormier; P Vincent
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-09       Impact factor: 3.267

2.  Genotypic investigation of Clostridium difficile in Prince Edward Island.

Authors:  H Martin; L P Abbott; D E Low; B Willey; M Mulvey; J Scott Weese
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-11       Impact factor: 2.471

Review 3.  Clostridium difficile infection: new insights into management.

Authors:  Sahil Khanna; Darrell S Pardi
Journal:  Mayo Clin Proc       Date:  2012-11       Impact factor: 7.616

Review 4.  Taking stock of infections and antibiotic resistance in the elderly and long-term care facilities: A survey of existing and upcoming challenges.

Authors:  S Augustine; R A Bonomo
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2011-09-09

5.  Evolutionary dynamics of Clostridium difficile over short and long time scales.

Authors:  Miao He; Mohammed Sebaihia; Trevor D Lawley; Richard A Stabler; Lisa F Dawson; Melissa J Martin; Kathryn E Holt; Helena M B Seth-Smith; Michael A Quail; Richard Rance; Karen Brooks; Carol Churcher; David Harris; Stephen D Bentley; Christine Burrows; Louise Clark; Craig Corton; Vicky Murray; Graham Rose; Scott Thurston; Andries van Tonder; Danielle Walker; Brendan W Wren; Gordon Dougan; Julian Parkhill
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-05       Impact factor: 11.205

6.  [Clostridium difficile-associated infections. How dangerous are the new strains?].

Authors:  A Kola
Journal:  Internist (Berl)       Date:  2010-02       Impact factor: 0.743

Review 7.  Clostridium difficile and inflammatory bowel disease: role in pathogenesis and implications in treatment.

Authors:  Orna Nitzan; Mazen Elias; Bibiana Chazan; Raul Raz; Walid Saliba
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

8.  Epidemiology of Clostridium difficile-associated disease at University Hospital Basel including molecular characterisation of the isolates 2006-2007.

Authors:  L Fenner; R Frei; M Gregory; M Dangel; A Stranden; A F Widmer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-06-17       Impact factor: 3.267

9.  Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain.

Authors:  Annie-Claude Labbé; Louise Poirier; Duncan Maccannell; Thomas Louie; Michel Savoie; Claire Béliveau; Michel Laverdière; Jacques Pépin
Journal:  Antimicrob Agents Chemother       Date:  2008-06-23       Impact factor: 5.191

10.  Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium.

Authors:  Richard A Stabler; Miao He; Lisa Dawson; Melissa Martin; Esmeralda Valiente; Craig Corton; Trevor D Lawley; Mohammed Sebaihia; Michael A Quail; Graham Rose; Dale N Gerding; Maryse Gibert; Michel R Popoff; Julian Parkhill; Gordon Dougan; Brendan W Wren
Journal:  Genome Biol       Date:  2009-09-25       Impact factor: 13.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.